Dihydroxymethyl-benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Dihydroxymethyl-benzoic acid
• 英文别名: 2-(dihydroxymethyl)benzoic acid
• 化学式: C₈H₈O₄
• 分子量: 168.15
• InChiKey: VKVMEOCOLGGPBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Chemical Process for the Preparation of an Amido-Phenoxybenzoic Acid Compound
  申请人：Hopes Phillip Anthony

  公开号：US20080300412A1

  公开（公告）日：2008-12-04

  A process for making a compound of formula (I), which is useful as an intermediate to compounds which activate glucokinase, is described, (wherein P 1 , R 1 and R 2 are as defined in the description).

  一种制备化合物的方法，该化合物的化学式为（I），该化合物可作为激活葡萄糖激酶的化合物的中间体，详细描述了该方法（其中P1、R1和R2如描述中所定义）。
• [EN] AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS<br/>[FR] DERIVES D'AMINONICOTINATE JOUANT LE ROLE DE MODULATEURS DE GLUCOKINASE (GLK)
  申请人：ASTRAZENECA AB

  公开号：WO2003000267A1

  公开（公告）日：2003-01-03

  The invention related to novel compounds of Formula (I) or a salt, solvate or prodrug thereof, wherein R?1?, R2, R3, n and m are as described in the specification, useful in the treatment of a (A chemical formula should be inserted here - please see paper copy enclosed) Formula (I) disease or condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to methods for preparing compounds of Formula (I) and their use as medicaments in the treatment of diseases mediated by glucokinase.

  本发明涉及一种新型化合物的公式（I）或其盐，溶剂化物或前药，其中R?1？，R2，R3，n和m如规范中所述，对治疗通过葡萄糖激酶（GLK）介导的（这里应插入一种化学式-请参见随附的纸质副本）公式（I）疾病或病况有用，例如2型糖尿病。本发明还涉及制备公式（I）化合物的方法及其作为治疗由葡萄糖激酶介导的疾病的药物的用途。
• Amino nicotinate derivatives as glucokinase (GLK) modulators
  申请人：——

  公开号：US20040214868A1

  公开（公告）日：2004-10-28

  The invention related to novel compounds of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, useful in the treatment of a 1 disease or condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to methods for preparing compounds of Formula (I) and their use as medicaments in the treatment of diseases mediated by glucokinase.

  该发明涉及式（I）的新化合物或其盐，溶剂化合物或前药，其中R1，R2，R3，n和m如规范所述，在通过葡萄糖激酶（GLK）介导的疾病或症状的治疗中有用，例如2型糖尿病。该发明还涉及制备式（I）化合物的方法，以及它们作为药物治疗由葡萄糖激酶介导的疾病的用途。
• Protein tyrosine phosphatase inhibitors and methods of use thereof
  申请人：Blaskovich Arnold Thomas Mark

  公开号：US20060142250A1

  公开（公告）日：2006-06-29

  The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.

  本发明提供了式（I）和式（II）的化合物，这些化合物对于调节蛋白酪氨酸磷酸酶-1b（PTP1B）酶的生物活性是有用的。本发明的化合物可用于治疗PTP1B酶是因素的疾病和/或病况。这些疾病和/或病况包括但不限于1型糖尿病、2型糖尿病、葡萄糖耐量不足、胰岛素抵抗、肥胖症、高脂血症、高三酰甘油血症、高胆固醇血症、低高密度脂蛋白水平、动脉粥样硬化、血管再狭窄、炎症性肠病、胰腺炎、脂肪细胞肿瘤、脂肪细胞癌、脂肪肉瘤、脂质代谢异常、癌症和神经退行性疾病。
• PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Blaskovich Mark Arnold Thomas

  公开号：US20090131374A1

  公开（公告）日：2009-05-21

  The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.

  本发明提供了公式（I）和公式（II）的化合物，这些化合物对于调节蛋白酪氨酸磷酸酶-1b（PTP1B）酶的生物活性是有用的。本发明的化合物可用于治疗PTP1B酶是因素的疾病和/或病况。这些疾病和/或病况包括但不限于1型糖尿病，2型糖尿病，不足的葡萄糖耐受性，胰岛素抵抗，肥胖症，高脂血症，高三酰甘油血症，高胆固醇血症，低高密度脂蛋白水平，动脉粥样硬化，血管再狭窄，炎症性肠病，胰腺炎，脂肪细胞肿瘤，脂肪细胞癌，脂肪肉瘤，脂质代谢异常，癌症和神经退行性疾病。